CEO: David R. Elmaleh, PhD

Visit Website

AZTherapies is a clinical-stage biopharmaceutical company developing novel therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population.

Advancing a growing pipeline of candidates to treat patients with few therapeutic options, their lead program, ALZT-OP1 recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of disease. Following that lead program, they are advancing candidates for the treatment of post-ischemic stroke cognitive impairment, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other neurodegenerative diseases.